arrow-right-realarrow-rightarrow-rightback-to-topdoctordownloadfacebookinstagramlogologo-wordmarkcasttwitter
Close Modal

Research Publications

Arkana is a learning, teaching, innovating practice with one unifying passion – to actively work toward the day that our research yields breakthroughs that make our services unnecessary. Read about some of our latest publications below.


Recent Publications

1. Liapis H, Boils CL, Hennigar RA, Silva FG. Myoglobin casts in renal biopsies: Immunohistochemistry and Morphologic Spectrum. Human Pathology 2016.

2. Larsen CP and Walker PD. Response to C4d as a marker of masked immune deposits. Kidney Int. 2016. In press.

3. Shah P, Cooper JE, Lucia S, Boils C, Larsen CP, Wiseman AC. APOL1 polymorphisms in a deceased donor and early presentation of collapsing glomerulopathy and focal segmental glomerulosclerosis in two recipients. Am J Transplant. 2016 [epub ahead of print]

4. Larsen CP, Durfee T, Wilson JD, Beggs ML. A Custom Targeted Next Generation Sequencing Gene Panel for the Diagnosis of Genetic Nephropathies. Am J Kidney Dis. 2016 (in press)

5. Larsen CP, Beggs, ML, Wilson JD, Lathrop SL. Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico. Amyloid. 2016 [epub ahead of print]

6. Kurien AA, Larsen CP, Rajapurkar M, Bonsib SM, Walker PD. Lack of electron microscopy hinders correct renal biopsy diagnosis: A study from India. Ultrastruct Pathol. 2016 Jan; 40(1): 14–17.

7. Larsen CP, Ismail W, Kurtin P, Vrana J, Dasari S, Nasr SH. Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. Mod Pathol. Mod Pathol. 2016 Apr;29(4):416-20.

8. Kurien AA, Larsen CP, Cossey LN. Collagenofibrotic glomerulopathy. Clinical Kidney Journal. 2015 Oct;8(5):543-7.

9. Larsen CP, Messias NC, Walker PD, Fidler ME, Cornell LD, Hernandez LH, Alexander MP, Sethi S, Nasr SH.  Membranoproliferative Glomerulonephritis with Masked Monotypic Immunoglobulin Deposits. Kidney Int. 2015 Oct;88(4):867-73.

10. Nasr SH, Dogan A, Larsen CP. Leukocyte chemotactic factor 2-associated amyloidosis: An emerging disease with distinct clinicopathologic characteristics. Clin J Am Soc Nephrol. 2015 Nov 6;10(11):2084-93.

11. Larsen CP, Freedman BI. APOL1-associated nephropathy and the future of renal diagnostics. J Am Soc Nephrol. 2015 Jun;26(6):1232-5.

12. Boils CL, Nasr SH, Walker PD, Couser WG and Larsen CP. Update on Endocarditis-Associated Glomerulonephritis. Kidney International. 2015 Jun;87(6):1241-9.

13. Messias NM, Walker PD, Larsen CP. Paraffin Immunofluorescence in the Renal Pathology Laboratory: More Than a Salvage Technique. Modern Pathology. 2015 Jun;28(6):854-60.

14. Larsen CP. Leukocyte chemotactic factor 2 amyloidosis can be reliably diagnosed by immunohistochemical staining. Hum Pathol. 2014 Oct;45(10):2179.

15. Larsen CP, Messias NC, Walker PD. B7-1 Immunostaining in Proteinuric Kidney Disease. Am J Kidney Dis. 2014 Dec;64(6):1001-3.

16. Saeed M, Beggs ML, Walker PD, Larsen CP. PLA2R-Associated membranous glomerulopathy is modulated by common variants in PLA2R1 and HLA-DQA1 genes. Genes and Immunity. 2014 Dec;15(8):556-61.

17. Larsen CP, Beggs ML, Saeed M, Ambruzs JM, L Nicholas Cossey, Messias NC, Walker PD, Freedman BI. Histopathologic Findings Associated with APOL1 Risk Variants in Chronic Kidney Disease. Modern Pathology. Mod Pathol. 2014 Jan;28(1):95-102.

18. Cossey LN, Messias NC, Walker PD, Silva FG. Defining the spectrum of immunoglobulin A–dominant/codominant glomerular deposition in diabetic nephropathy. Human pathology 45(11): 2294-2301, 2014.

19. Bonomo JA, Ng MCY, Palmer ND, Keaton JM, Larsen CP, Hicks PJ, Langefield CD, Freedman BI, Bowden DW. Coding variants in NPHS1 modulate susceptibility to nephropathy in African Americans. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1434-1440.

20. Larsen CP, Beggs ML, Walker PD, Saeed M, Ambruzs JM, Messias NC. Histopathologic Effect of APOL1 Risk Alleles inPLA2R-Associated Membranous Glomerulopathy. Am J Kidney Dis. 2014. July; 64(1): 161-3.